<DOC>
	<DOC>NCT01968187</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and effectiveness of intranasal FE 992097 in children and adults with Prader-Willi Syndrome.</brief_summary>
	<brief_title>Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Hyperphagia</mesh_term>
	<criteria>Male or female 1018 years of age (both inclusive) Genetically confirmed diagnosis of PraderWilli Syndrome Determined to be in nutritional phase 3 by clinical assessment based on Miller et al, 2011 Known genetic, hormonal, or chromosomal cause of cognitive impairment other than PraderWilli Syndrome Presence of currently active psychotic symptoms Presence of any cardiovascular disorders, epilepsy, frequent migraines or severe asthma Previous diagnosis of autism spectrum disorder by a qualified healthcare provider Prior or concomitant use of a selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI), antipsychotic medication, wakefulnesspromoting drug, or thyroid hormone unless dosage has been stable â‰¥6 months at time of screening</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>